Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Operating Leases (2020 - 2026)

RxSight filings provide 6 years of Operating Leases readings, the most recent being $9.9 million for Q4 2025.

  • On a quarterly basis, Operating Leases fell 12.75% to $9.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.9 million, a 12.75% decrease, with the full-year FY2025 number at $9.9 million, down 12.75% from a year prior.
  • Operating Leases hit $9.9 million in Q4 2025 for RxSight, down from $10.3 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $11.3 million in Q4 2024 to a low of $908000.0 in Q1 2024.
  • Median Operating Leases over the past 5 years was $3.9 million (2022), compared with a mean of $5.7 million.
  • Biggest five-year swings in Operating Leases: tumbled 61.16% in 2024 and later surged 1110.02% in 2025.
  • RxSight's Operating Leases stood at $3.6 million in 2021, then dropped by 21.58% to $2.9 million in 2022, then crashed by 57.6% to $1.2 million in 2023, then soared by 834.93% to $11.3 million in 2024, then fell by 12.75% to $9.9 million in 2025.
  • The last three reported values for Operating Leases were $9.9 million (Q4 2025), $10.3 million (Q3 2025), and $10.6 million (Q2 2025) per Business Quant data.